文献速递MDS 与骨髓增殖性肿瘤

DNA甲基转移酶抑制剂单药治疗MDS的历史预期:联合治疗何时才算真正「有前景」?

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"?
PubMed 文献 · Blood Adv · 2022-01-01

该综述汇总了高危骨髓增生异常综合征(HR-MDS)中阿扎胞苷或地西他滨单药治疗研究,共1908例患者,总缓解率24%(95%CI 0.22-0.26),完全缓解率14%。阿扎胞苷组血液学改善率38%高于地西他滨组15%,而地西他滨组骨髓总缓解率29%高于阿扎胞苷组21%,完全缓解率两者相似。作者认为影响缓解的变量包括DNA甲基转移酶抑制剂(DNMTI)骨架和入组患者IPSS风险分布。

要点

  • HR-MDS中DNMTI单药完全缓解率低且不能治愈。
  • 1908例患者总缓解率24%,完全缓解率14%。
  • 阿扎胞苷血液学改善率38%高于地西他滨15%。

核心结论

  • DNMTI单药治疗HR-MDS完全缓解率低且不能治愈,早期联合试验常被称为「有前景」但后续随机试验多未显示获益。
  • 影响MDS缓解的变量包括特定DNMTI骨架和入组患者IPSS风险分布,考虑这些因素有助于识别哪些早期联合方案值得在更大随机试验中评估。

研究设计与样本

  • 综述了MDS中阿扎胞苷或地西他滨单药治疗研究,收集基线人口学(包括IPSS风险、DNMTI、疾病特征)和缓解变量(包括生存、骨髓和血液学缓解)。
  • 采用Meta分析技术计算跨研究的汇总估计,并使用二项设计估计设计显示联合治疗优于单药的2期研究所需的操作特征。

主要发现

  • 1908例患者中,总缓解率(ORR)为24%(n=464;95%CI 0.22-0.26):完全缓解(CR)267例(14%),部分缓解68例(4%),骨髓完全缓解129例(7%)。
  • 在报告血液学缓解的1604例患者中,476例(30%;95%CI 0.27-0.32)报告血液学改善(HI)。
  • 阿扎胞苷组达到HI的患者比例(38%;95%CI 0.35-0.41)高于地西他滨组(15%;95%CI 0.13-0.19)。
  • 地西他滨组骨髓ORR(29%;95%CI 0.26-0.33)高于阿扎胞苷组(21%;95%CI 0.19-0.23)。
  • 两种DNMTI的CR率相似:阿扎胞苷组13%,地西他滨组16%。

关键数值与推荐

  • 总缓解率24%(n=464;95%CI 0.22-0.26),其中CR 14%(267例)、部分缓解4%(68例)、骨髓完全缓解7%(129例)。
  • 血液学改善率30%(476/1604;95%CI 0.27-0.32)。
  • 阿扎胞苷组HI率38%(95%CI 0.35-0.41) vs 地西他滨组15%(95%CI 0.13-0.19)。
  • 地西他滨组骨髓ORR 29%(95%CI 0.26-0.33) vs 阿扎胞苷组21%(95%CI 0.19-0.23)。
  • CR率:阿扎胞苷组13% vs 地西他滨组16%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA methyltransferase inhibitors (DNMTIs) for patients with higher risk myelodysplastic syndromes (HR-MDS) have low complete remission rates and are not curative. Early DNMTI combination clinical trials in HR-MDS are often termed "promising," but many randomized trials subsequently failed to show benefit. Clearer understanding of when a combination is likely to improve upon DNMTI monotherapy would inform randomized studies. We reviewed MDS azacitidine or decitabine monotherapy studies. We collected baseline demographics including International Prognostic Scoring System (IPSS) risk, DNMTI, disease characteristics; and response variables including survival and marrow and hematologic responses. Aggregate estimates across studies were calculated using meta-analyses techniques. Using a binomial design, we estimated the necessary operating characteristics to design a phase 2 study showing improved efficacy of a combination over monotherapy. Among 1908 patients, the overall response rate (ORR) was 24% (n = 464; 95% confidence interval [CI], 0.22-0.26): 267 complete response (CR, 14%), 68 partial response (4%), and 129 marrow complete remission (7%). Among 1604 patients for whom a hematologic response was reported, 476 (30%; 95% CI, 0.27-0.32) reported hematologic improvement (HI). More patients treated with azacitidine achieved HI (38%; 95% CI, 0.35-0.41) compared with decitabine (15%; 95% CI, 0.13-0.19), whereas the marrow ORR rate was higher with decitabine (29%; 95% CI, 0.26-0.33) compared with azacitidine (21%; 95% CI, 0.19-0.23). CR rates were similar between DNMTIs: 13% with azacitidine and 16% with decitabine. Variables that influence MDS response include the specific DNMTI backbone and the distribution of IPSS risk of patients enrolled on a trial. Considering these factors can help identify which early combination approaches are worth assessing in larger randomized trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Brunner AM, Fell G, Steensma DP, et al. Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly "promising"? Blood Adv. 2022. PMID: 35143613. doi:10.1182/bloodadvances.2021006357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。